Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports
Go Back
View Our Subscription Options

Search

Descriptive Alt Text

Filters

Showing results 977–984 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Biohaven Ltd. Troriluzole Obsessive compulsive disorder (OCD) Phase 3 Ongoing Oral Psychiatric
Biohaven Ltd. BHV-2100 Acute migraine Phase 2 Ongoing Intravenous Neurology
Biohaven Ltd. BHV-8000 Early Alzheimer's disease Phase 2/3 Ongoing Oral Neurology
Biohaven Ltd. Nurtec ODT (rimegepant) Refractory trigeminal neuralgia Phase 2 Trial Completed Oral Neurology
BioLineRx Ltd. Motixafortide (BL-8040), gemcitabine, nab-paclitaxel and LIBTAYO (cemiplimab) - (Columbia University trial) - (CheMo4METPANC) First-line pancreatic ductal adenocarcinoma (PDAC) Phase 2b Ongoing Intravenous Oncology
BioLineRx Ltd. Motixafortide (BL-8040) - BLAST Consolidation treatment for AML cancer patients Phase 2b Trial Discontinued Subcutaneous Oncology
BioLineRx Ltd. Motixafortide with an anti-PD-1 and chemotherapy Pancreatic ductal adenocarcinoma (PDAC) Phase 2b Ongoing Intravenous Oncology
BioLineRx Ltd. Motixafortide - (China trial) Pancreatic ductal adenocarcinoma Phase 2b Trial Planned Subcutaneous Oncology
1…121122123124125…553
Your trusted source for drug reimbursement data and buy-and-bill insights.
Platform
Resources
Tools
Search Drugs
Newsletter
Reimbursement updates, drug pricing news.
© 2026 BuyandBill.com, All Rights Reserved.
HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, America's Health Insurance Plans, and Blue Cross and Blue Shield Association). CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.